Latest Annual Filing

Fiscal Year Ended Jul 31, 2017

View Filing

Stock Information

Company Overview

OncoSec Medical Incorporated is a biopharmaceutical company developing its investigational Intratumoral IL-12 intratumoral cancer immunotherapy. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of Intratumoral IL-12 have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's lead program evaluating Intratumoral IL-12 for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate Intratumoral IL-12 in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches.

Investor Presentation

Investor Presentation

Download Investor Presentation

Leadership

Having accumulated decades of collective experience across a variety of fields, our leadership team is the source of our success.

Investor Contact Information

Company

OncoSec Medical Incorporated
3565 General Atomics Ct.
San Diego, CS 92121

Investor Relations

T: 855-ONCOSEC (855-662-6732)
investors@oncosec.com

Transfer Agent

Nevada Agency and Transfer Company
50 W. Liberty St.
Suite 880
Reno, NV 89501
T: 775-322-0626
info@natco.org
www.natco.org